Login Register
English
0

Cart

$ 0
OR
Catalog no Product name Protocol name IF Magazine title
A23410 Dylight 594, Goat Anti-Mouse IgG Tumor cell-derived SPON2 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by activating PYK2 in CRC(A23410-7) 7 J Exp Clin Cancer Res
A23440 Dylight 594, Goat Anti-Rat IgG Tumor cell-derived SPON2 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by activating PYK2 in CRC(A23440-7) 7 J Exp Clin Cancer Res
KTA1020 Cell Counting Kit-8 (CCK-8) Tumor necrosis factor alpha preconditioned umbilical cord mesenchymal stem cell-derived extracellular vesicles enhance the inhibition of necroptosis of Acinar cells …(KTA1020-2.8997) 2.8997 Ecotoxicology and Environmental Safety
KTB1600 CheKine™ Micro Reduced Glutathione (GSH) Assay Kit Tumor Microenvironment-Activatable Metal-Phenolic Nanoformulations for Ultrasound-Boosted Ferroptosis through Triple Regulatory Pathways(KTB1600-18.5) 18.5 Nat Commun
A23420 Dylight 594, Goat Anti-Rabbit IgG Tumor Necrosis Factor Receptor Superfamily Member 12A Enhances Retinal Ganglion Cell Survival and Promotes Axon Regeneration(A23420-4.1998) 4.1998 Antioxidants
A25012 IPKine™ HRP, Goat Anti-Mouse IgG LCS Tumor suppressor DRD2 facilitates M1 macrophages and restricts NF-κB signaling to trigger pyroptosis in breast cancer(A25012-13.3) 13.3 Archives of oral biology
A01010 Tumoral microvesicle–activated glycometabolic reprogramming in fibroblasts promotes the progression of oral squamous cell carcinoma(A01010-6) 6 FASEB J
A01020 Tumoral microvesicle–activated glycometabolic reprogramming in fibroblasts promotes the progression of oral squamous cell carcinoma(A01020-6) 6 FASEB J
A01030 Tumoral microvesicle–activated glycometabolic reprogramming in fibroblasts promotes the progression of oral squamous cell carcinoma(A01030-6) 6 FASEB J
A25012 IPKine™ HRP, Goat Anti-Mouse IgG LCS Tumor-associated macrophages confer colorectal cancer 5-fluorouracil resistance by promoting MRP1 membrane translocation via an intercellular CXCL17 …(A25012-9.6) 9.6 Drug Deliv